Fibrocell Science (NASDAQ:FCSC) Downgraded by ValuEngine

ValuEngine cut shares of Fibrocell Science (NASDAQ:FCSC) from a hold rating to a sell rating in a research report released on Saturday, ValuEngine reports.

Several other analysts have also weighed in on the company. Zacks Investment Research lowered Fibrocell Science from a buy rating to a hold rating in a report on Tuesday, June 18th. HC Wainwright reissued a buy rating and issued a $22.00 target price on shares of Fibrocell Science in a report on Thursday, March 28th.

Fibrocell Science stock opened at $1.91 on Friday. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.59 and a quick ratio of 3.59. The firm has a market capitalization of $19.33 million, a price-to-earnings ratio of -1.32 and a beta of 1.75. Fibrocell Science has a fifty-two week low of $1.45 and a fifty-two week high of $3.36. The firm has a fifty day moving average price of $1.97.

Fibrocell Science (NASDAQ:FCSC) last posted its earnings results on Wednesday, May 15th. The company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.07). On average, equities research analysts anticipate that Fibrocell Science will post -1.31 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Fibrocell Science stock. Apis Capital Advisors LLC bought a new stake in Fibrocell Science Inc (NASDAQ:FCSC) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $48,000. Apis Capital Advisors LLC owned about 0.26% of Fibrocell Science as of its most recent filing with the Securities & Exchange Commission. 28.04% of the stock is owned by institutional investors.

Fibrocell Science Company Profile

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Further Reading: What is channel trading?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit